专利检索 ap:("NantBioScience, Inc.") AND inv:"NALLAN, Laxman" 第 1 页

1.

发明公开
PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS 审中-公开
标题翻译：嘧啶衍生物作为激酶抑制剂及其治疗应用

公开(公告)号：EP3261637A1

公开(公告)日：2018-01-03

申请号：EP15883597.5

申请日：2015-02-27

申请人： NantBioScience, Inc.

发明人： TAO, Chunlin , WANG, Qinwei , NALLAN, Laxman , HO, David , POLAT, Tulay , ARP, Forrest , WEINGARTEN, Paul

IPC分类号： A61K31/404

CPC分类号： C07D403/12 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P29/00 , A61P35/00 , A61P37/00 , C07D401/14 , C07D403/14 , C07D405/14 , C07D417/14 , C07D487/04

摘要： The present invention provides antitumor agents comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof, methods for making novel compounds and methods for using the compounds. The compounds and compositions in accordance with the invention have utility in treatment of a variety of diseases and have kinase inhibitory activities.

2.

发明授权
PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS 有权

公开(公告)号：EP3261638B1

公开(公告)日：2019-05-08

申请号：EP16756548.0

申请日：2016-02-29

申请人： NantBioScience, Inc.

发明人： TAO, Chunlin , WANG, Qinwei , NALLAN, Laxman , HO, David , POLAT, Tulay , ARP, Forrest , WEINGARTEN, Paul

IPC分类号： A61K31/404 , A61K31/506 , C07D401/14 , C07D403/12 , C07D405/14 , C07D403/14 , C07D417/14 , C07D487/14 , A61P29/00 , A61P35/00 , A61P37/00

3.

发明公开
PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS AND THEIR THERAPEUTICAL APPLICATIONS 审中-公开

公开(公告)号：EP3261638A1

公开(公告)日：2018-01-03

申请号：EP16756548.0

申请日：2016-02-29

申请人： NantBioScience, Inc.

发明人： TAO, Chunlin , WANG, Qinwei , NALLAN, Laxman , HO, David , POLAT, Tulay , ARP, Forrest , WEINGARTEN, Paul

IPC分类号： A61K31/404 , A61K31/506 , C07D401/12 , C07D403/10

CPC分类号： C07D403/12 , A61K31/506 , A61K31/5377 , A61K45/06 , A61P29/00 , A61P35/00 , A61P37/00 , C07D401/14 , C07D403/14 , C07D405/14 , C07D417/14 , C07D487/04

摘要： The present invention provides antitumor agents comprising substituted pyrimidine derivatives and pharmaceutically-acceptable formulations thereof, methods for making novel compounds and methods for using the compounds. The compounds and compositions in accordance with the invention have utility in treatment of a variety of diseases and have kinase inhibitory activities.